Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1932734 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Kangyu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tetracyclines, Carbapenem-Resistant Enterobacteriaceae, Klebsiella pneumoniae. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Eravacycline is a novel fluorocycline with potent activity against carbapenem-resistant Enterobacterales (CRE). However, comparative validation of gradient diffusion (MIC Test Strip, MTS) and disk diffusion (DD) against reference broth microdilution (BMD) specifically in CRE isolates remains limited, particularly under region-specific breakpoint systems.
Methods
This study evaluated the performance of the MTS and DD against BMD for eravacycline susceptibility testing in 358 CRE clinical isolates (174 carbapenem-resistant Klebsiella pneumoniae , CRKP and 144 carbapenem-resistant Escherichia coli , CREC), using both U.S. Food and Drug Administration (FDA) and Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (ChinaCAST) breakpoints. Categorical agreement (CA), essential agreement (EA), major error (ME), and very major error (VME) were assessed according to CLSI M52 criteria, and Bland-Altman analysis was performed for quantitative agreement between MTS and BMD.
Results
BMD showed MIC 50 /MIC 90 of 0.25/1 mg/L, with overall susceptibility rate of 81.2% by FDA breakpoints. For MTS, overall CA and EA were 92.8% and 92.5%, but VME was 33.8% under FDA breakpoints, concentrated in CRKP (35.5%). Under ChinaCAST breakpoints, CRKP CA increased to 94.8%, yet VME decreased to 18.2% and ME increased to 4.3%. For DD, overall CA was 89.9% with VME of 32.3%; only CREC under FDA breakpoints achieved acceptable CA (97.9%) and error rates, whereas ChinaCAST breakpoints yielded unacceptable CA (77.0-77.8%) and elevated ME (22.4-24.5%) for both species.
Conclusions
Eravacycline retains potent in vitro activity against CRE. MTS is suitable for routine testing of CREC, and DD is reliable for CREC under FDA breakpoints. For CRKP, neither method satisfied CLSI M52 criteria, and reference BMD remains indispensable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Postdoctoral Research Station, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
- Department of Laboratory Medicine, Liaocheng Second People's Hospital, Liaocheng, China.
- Department of Laboratory Medicine, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
- Department of Laboratory Medicine, Binzhou People's Hospital, Binzhou, China.
- Shandong Provincial Key Medical and Health Laboratory of Anti-Drug Resistant Drug Research, The Affiliated Taian City Central Hospital of Qingdao University, Taian, China.
Zitieren
APA
Wang, K., Tian, J., Wu, T., Dong, C., Wang, X., Feng, Q., & Zhang, Z. (2026). Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1932734
Vancouver
Wang K, Tian J, Wu T, Dong C, Wang X, Feng Q, et al. Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1932734
BibTeX
@article{Wang2026,
author = {Wang, Kangyu and Tian, Jinjing and Wu, Tingchao and Dong, Chunzhong and Wang, Xinying and Feng, Qiang and Zhang, Zhijun},
title = {Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1932734}
}
EUVIMED